Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis

Clinical article

View More View Less
  • 1 Departments of Neurological Surgery,
  • | 2 Pediatrics,
  • | 3 Neurology,
  • | 4 Anesthesiology and Peri-Operative Medicine,
  • | 5 Pathology,
  • | 6 Diagnostic Radiology, and
  • | 7 Molecular and Medical Genetics, Oregon Health & Science University;
  • | 8 Doernbecher Children's Hospital, Portland, Oregon;
  • | 9 StemCells, Inc., Newark;
  • | 10 Department of Pathology, Stanford University Medical School, Stanford; and
  • | 11 Department of Pediatrics Palo Alto Medical Foundation, Los Altos, California
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
Print or Print + Online

Object

Infantile and late-infantile neuronal ceroid lipofuscinoses (NCLs) are invariably fatal lysosomal storage diseases associated with defects in lysosomal enzyme palmitoyl-protein thioesterase 1 (PPT-1) or tripeptidyl peptidase 1 (TPP1) activity. Previous preclinical studies have demonstrated that human CNS stem cells (HuCNS-SCs) produce both PPT-1 and TPP1 and result in donor cell engraftment and reduced accumulation of storage material in the brain when tested in an NCL mouse model.

Methods

HuCNS-SC transplantation was tested in an open-label dose-escalation Phase I clinical trial as a potential treatment for infantile and late-infantile NCL. Study design included direct neurosurgical transplantation of allogeneic HuCNS-SCs into the cerebral hemispheres and lateral ventricles accompanied by 12 months of immunosuppression.

Results

Six children with either the infantile or late-infantile forms of NCL underwent low- (3 patients) and high- (3 patients) dose transplantation of HuCNS-SCs followed by immunosuppression. The surgery, immunosuppression, and cell transplantation were well tolerated. Adverse events following transplantation were consistent with the underlying disease, and none were directly attributed to the donor cells. Observations regarding efficacy of the intervention were limited by the enrollment criteria requiring that patients be in advanced stages of disease.

Conclusions

This study represents the first-in-human clinical trial involving transplantation of a purified population of human neural stem cells for a neurodegenerative disorder. The feasibility of this approach and absence of transplantation-related serious adverse events support further exploration of HuCNS-SC transplantation as a potential treatment for select subtypes of NCL, and possibly for other neurodegenerative disorders. Clinical trial registration no.: NCT00337636 (ClinicalTrials.gov).

Abbreviations used in this paper:

BSID-II = Bayley Scales of Infant Development II; CAS = Callier-Azusa G-Scale; DMC = Data Monitoring Committee; EEG = electroencephalography; HuCNS-SC = human CNS stem cell; INCL = infantile NCL; LINCL = late-infantile NCL; MMF = mycophenolate mofetil; NCL = neuronal ceroid lipofuscinosis; OHSU = Oregon Health & Science University; PCR = polymerase chain reaction.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
  • 1

    Andres RH, , Meyer M, , Ducray AD, & Widmer HR: Restorative neuroscience: concepts and perspectives. Swiss Med Wkly 138:155172, 2008

  • 2

    Bennett MJ, & Hofmann SL: The neuronal ceroid-lipofuscinoses (Batten disease): a new class of lysosomal storage diseases. J Inherit Metab Dis 22:535544, 1999

    • Search Google Scholar
    • Export Citation
  • 3

    Carpenter MK, , Cui X, , Hu ZY, , Jackson J, , Sherman S, & Seiger A, et al.: In vitro expansion of a multipotent population of human neural progenitor cells. Exp Neurol 158:265278, 1999

    • Search Google Scholar
    • Export Citation
  • 4

    Freed CR, , Greene PE, , Breeze RE, , Tsai WY, , DuMouchel W, & Kao R, et al.: Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344:710719, 2001

    • Search Google Scholar
    • Export Citation
  • 5

    Gupta P, , Soyombo AA, , Atashband A, , Wisniewski KE, , Shelton JM, & Richardson JA, et al.: Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice. Proc Natl Acad Sci U S A 98:1356613571, 2001

    • Search Google Scholar
    • Export Citation
  • 6

    Haltia M: The neuronal ceroid-lipofuscinoses: from past to present. Biochim Biophys Acta 1762:850856, 2006

  • 7

    Jalanko A, & Braulke T: Neuronal ceroid lipofuscinoses. Biochim Biophys Acta 1793:697709, 2009

  • 8

    Keene CD, , Sonnen JA, , Swanson PD, , Kopyov O, , Leverenz JB, & Bird TD, et al.: Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 68:20932098, 2007

    • Search Google Scholar
    • Export Citation
  • 9

    Kohlschütter A, & Schulz A: Towards understanding the neuronal ceroid lipofuscinoses. Brain Dev 31:499502, 2009

  • 10

    Le Belle JE, & Svendsen CN: Stem cells for neurodegenerative disorders: where can we go from here?. BioDrugs 16:389401, 2002

  • 11

    Lee JP, , Jeyakumar M, , Gonzalez R, , Takahashi H, , Lee PJ, & Baek RC, et al.: Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med 13:439447, 2007

    • Search Google Scholar
    • Export Citation
  • 12

    Lindvall O, , Brundin P, , Widner H, , Rehncrona S, , Gustavii B, & Frackowiak R, et al.: Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247:574577, 1990

    • Search Google Scholar
    • Export Citation
  • 13

    Lindvall O, & Kokaia Z: Stem cells for the treatment of neurological disorders. Nature 441:10941096, 2006

  • 14

    Lindvall O, & Kokaia Z: Stem cells in human neurodegenerative disorders—time for clinical translation?. J Clin Invest 120:2940, 2010

  • 15

    Mendez I, , Dagher A, , Hong M, , Hebb A, , Gaudet P, & Law A, et al.: Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line–derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J Neurosurg 92:863869, 2000

    • Search Google Scholar
    • Export Citation
  • 16

    Mole SE, , Williams RE, & Goebel HH: Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics 6:107126, 2005

    • Search Google Scholar
    • Export Citation
  • 17

    Olanow CW, , Goetz CG, , Kordower JH, , Stoessl AJ, , Sossi V, & Brin MF, et al.: A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54:403414, 2003

    • Search Google Scholar
    • Export Citation
  • 18

    Politis M, , Wu K, , Loane C, , Quinn NP, , Brooks DJ, & Rehncrona S, et al.: Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med 2:38ra46, 2010

    • Search Google Scholar
    • Export Citation
  • 19

    Santavuori P: Neuronal ceroid-lipofuscinoses in childhood. Brain Dev 10:8083, 1988

  • 20

    Sawada T, , Tanaka A, , Seto T, , Maeda M, , Jikihara I, & Yamaguchi E, et al.: Cell therapy for the brain involvement on lysosomal storage disease. J Inherit Metab Dis 29:Suppl 1 35, 2006. (Abstract)

    • Search Google Scholar
    • Export Citation
  • 21

    Schwartz PH, & Brick DJ: Stem cell therapies for the lysosomal storage diseases—the quintessential neurodegenerative diseases. Curr Stem Cell Res Ther 3:8898, 2008

    • Search Google Scholar
    • Export Citation
  • 22

    Sidman RL, , Li J, , Stewart GR, , Clarke J, , Yang W, & Snyder EY, et al.: Injection of mouse and human neural stem cells into neonatal Niemann-Pick A model mice. Brain Res 1140:195204, 2007

    • Search Google Scholar
    • Export Citation
  • 23

    Sleat DE, , Donnelly RJ, , Lackland H, , Liu CG, , Sohar I, & Pullarkat RK, et al.: Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 277:18021805, 1997

    • Search Google Scholar
    • Export Citation
  • 24

    Snyder EY, , Daley GQ, & Goodell M: Taking stock and planning for the next decade: realistic prospects for stem cell therapies for the nervous system. J Neurosci Res 76:157168, 2004

    • Search Google Scholar
    • Export Citation
  • 25

    Tamaki S, , Eckert K, , He D, , Sutton R, , Doshe M, & Jain G, et al.: Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. J Neurosci Res 69:976986, 2002

    • Search Google Scholar
    • Export Citation
  • 26

    Tamaki SJ, , Jacobs Y, , Dohse M, , Capela A, , Cooper JD, & Reitsma M, et al.: Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. Cell Stem Cell 5:310319, 2009

    • Search Google Scholar
    • Export Citation
  • 27

    Taupin P: Therapeutic potential of adult neural stem cells. Recent Patents CNS Drug Discov 1:299303, 2006

  • 28

    Uchida N, , Buck DW, , He D, , Reitsma MJ, , Masek M, & Phan TV, et al.: Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 97:1472014725, 2000

    • Search Google Scholar
    • Export Citation
  • 29

    Vesa J, , Hellsten E, , Verkruyse LA, , Camp LA, , Rapola J, & Santavuori P, et al.: Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 376:584587, 1995

    • Search Google Scholar
    • Export Citation
  • 30

    Worgall S, , Sondhi D, , Hackett NR, , Kosofsky B, , Kekatpure MV, & Neyzi N, et al.: Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 19:463474, 2008

    • Search Google Scholar
    • Export Citation
  • 31

    Zietlow R, , Lane EL, , Dunnett SB, & Rosser AE: Human stem cells for CNS repair. Cell Tissue Res 331:301322, 2008

  • a.

    Mendez I, , Dagher A, , Hong M, , Hebb A, , Gaudet P, & Law A, et al.: Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line–derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J Neurosurg 92:863869, 2000

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 1839 701 91
Full Text Views 256 36 8
PDF Downloads 266 43 6
EPUB Downloads 0 0 0